Advances in transplantation tolerance

Lancet

Volumn 357, Issue 9272, 2001, Pages 1959-1963

  Yu, Xue Zhong ^a,b   Carpenter, Paul ^a,b   Anasetti, Claudio ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIGEN; AZATHIOPRINE; CD28 ANTIGEN; CD40 LIGAND; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; GLYCOPROTEIN GP 39; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; CELL ACTIVATION; CELL DIVISION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOSIS INHIBITION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0035897909     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05068-6     Document Type: Note

References (55)

1. T cell tolerance by clonal elimination in the thymus
2. Self-nonself discrimination by T cells
3. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
4. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
5. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
6. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
7. Stable mixed haemopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
8. Haemopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
9. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
10. Infusion of donor leukocytes to induce tolerance in organ allograft recipients
11. Cyclosporin a as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors: Preliminary results of a European multicentre trial
12. Multicenter randomized trial comparing tacrolimus (FK506) and ciclosporin in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
13. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
14. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial
15. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
16. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
17. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
18. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation
19. The male-specific histocompatibility antigen, H-Y: A history of transplantation, immune response genes, sex determination and expression cloning
20. Anti-lymphocytic antibodies and marrow transplantation: 3-Effect of heterologous anti-brain antibodies on acute secondary disease in mice
21. Activation of transplant immunity: Effect of donor leukocytes on thyroid allograft rejection
22. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
23. Dendritic cells as regulators of immune reactivity: Implications for transplantation
24. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis
25. Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment
26. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
27. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
28. 2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
29. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
30. A cell culture model for T lymphocyte clonal anergy
31. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones
32. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
33. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL
34. Role of CD28 in acute graft-versus-host disease
35. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg
36. CD28/B7 system of T cell costimulation
37. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
38. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
39. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28
40. CD28-specific antibody prevents graft-versus-host disease in mice
41. Differential T cell costimulatory requirements in CD28-deficient mice
42. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
43. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand
44. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
45. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation
46. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
47. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
48. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
49. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
50. Inhibition of cell cycle progression by rapamycin incudes T cell clonal anergy even in the presence of costimulation
51. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
52. Compromised kidney graft rejection response in vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus
53. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
54. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
55. Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing CTLA4